|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




* Center for Immunotherapy of Cancer and Infectious Diseases,
Division of Cardiology, and
UConn Center on Aging, Department of Medicine, University of Connecticut School of Medicine, Farmington, CT 06030;
Department of Statistics, University of Connecticut, Storrs, CT 06269; and
¶
Department of Medical Microbiology and Immunology and
||
Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
It is commonly held that increased risk of influenza in the elderly is due to a decline in the Ab response to influenza vaccination. This study prospectively evaluated the relationship between the development of influenza illness, and serum Ab titers and ex vivo cellular immune responses to influenza vaccination in community dwelling older adults including those with congestive heart failure (CHF). Adults age 60 years and older (90 subjects), and 10 healthy young adult controls received the 2003-04 trivalent inactivated influenza vaccine. Laboratory diagnosed influenza (LDI) was documented in 9 of 90 older adults. Pre- and postvaccination Ab titers did not distinguish between subjects who would subsequently develop influenza illness (LDI subjects) and those who would not (non-LDI subjects). In contrast, PBMC restimulated ex vivo with live influenza virus preparations showed statistically significant differences between LDI and non-LDI subjects. The mean IFN-
:IL-10 ratio in influenza A/H3N2-stimulated PBMC was 10-fold lower in LDI vs non-LDI subjects. Pre-and postvaccination granzyme B levels were significantly lower in CHF subjects with LDI compared with subjects without LDI. In non-CHF subjects with LDI, granzyme B levels increased to high levels at the time of influenza infection. In conclusion, measures of the ex vivo cellular immune response to influenza are correlated with protection against influenza while serum Ab responses may be limited as a sole measure of vaccine efficacy in older people. Ex vivo measures of the cell-mediated immune response should be incorporated into evaluation of new vaccines for older adults.
This article has been cited by other articles:
![]() |
A. Holvast, S. van Assen, A. de Haan, A. Huckriede, C. A. Benne, J. Westra, A. Palache, J. Wilschut, C. G. M. Kallenberg, and M. Bijl Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study Rheumatology, October 1, 2009; 48(10): 1294 - 1299. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Laddy, J. Yan, A. S. Khan, H. Andersen, A. Cohn, J. Greenhouse, M. Lewis, J. Manischewitz, L. R. King, H. Golding, et al. Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus J. Virol., May 1, 2009; 83(9): 4624 - 4630. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Assarsson, H.-H. Bui, J. Sidney, Q. Zhang, J. Glenn, C. Oseroff, I. N. Mbawuike, J. Alexander, M. J. Newman, H. Grey, et al. Immunomic Analysis of the Repertoire of T-Cell Specificities for Influenza A Virus in Humans J. Virol., December 15, 2008; 82(24): 12241 - 12251. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Eaton, A. C. Maue, S. L. Swain, and L. Haynes Bone Marrow Precursor Cells from Aged Mice Generate CD4 T Cells That Function Well in Primary and Memory Responses J. Immunol., October 1, 2008; 181(7): 4825 - 4831. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Terajima, J. Cruz, A. M. Leporati, L. Orphin, J. A. B. Babon, M. D. T. Co, P. Pazoles, J. Jameson, and F. A. Ennis Influenza A Virus Matrix Protein 1-Specific Human CD8+ T-Cell Response Induced in Trivalent Inactivated Vaccine Recipients J. Virol., September 15, 2008; 82(18): 9283 - 9287. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Jones, K. Clise-Dwyer, G. Huston, J. Dibble, S. Eaton, L. Haynes, and S. L. Swain Impact of Post-Thymic Cellular Longevity on the Development of Age-Associated CD4+ T Cell Defects J. Immunol., April 1, 2008; 180(7): 4465 - 4475. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Durando, D. Fenoglio, A. Boschini, F. Ansaldi, G. Icardi, L. Sticchi, A. Renzoni, P. Fabbri, A. Ferrera, A. Parodi, et al. Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults Clin. Vaccine Immunol., February 1, 2008; 15(2): 253 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Huaman, L. B. Martin, E. Malkin, D. L. Narum, L. H. Miller, S. Mahanty, and C. A. Long Ex Vivo Cytokine and Memory T Cell Responses to the 42-kDa Fragment of Plasmodium falciparum Merozoite Surface Protein-1 in Vaccinated Volunteers J. Immunol., February 1, 2008; 180(3): 1451 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Long, J. Michaelsson, C. P. Loo, W. M. Ballan, B.-A. N. Vu, F. M. Hecht, L. L. Lanier, J. M. Chapman, and D. F. Nixon Elevated Frequency of Gamma Interferon-Producing NK Cells in Healthy Adults Vaccinated against Influenza Virus Clin. Vaccine Immunol., January 1, 2008; 15(1): 120 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Min, A. Panoskaltsis-Mortari, M. Kuro-o, G. A. Hollander, B. R. Blazar, and K. I. Weinberg Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging Blood, March 15, 2007; 109(6): 2529 - 2537. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |